证券代码： 301097 证券简称：天益医疗 公告编号：2023-043 宁波天益医疗器械股份有限公司 2023 年半年度募集资金存放与使用情况专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及《深圳证券交易所创业板上市公司自律监 管指南第 2 号——公告格式》的相关规定，本公司就 2023 年半年度募集资金存 放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首次 公开发行股票注册的批复》(证监许可[2021]3939 号)同意注册，公司首次公开发 行人民币普通股（A 股）1,473.68 万股，发行价格为人民币 52.37 元/股，实际募 集资金总额为人民币 771,768,415.54 元，扣除承销费、保荐费以及各项其他发行 费用人民币 77,205,206.61 （ 不 ...

本表已于 2023 年 8 月 25 日获董事会批准。 宁波天益医疗器械股份有限公司 2023 年 1-6 月 非经营性资金占用及其他关联资金往来情况汇总表 注：1、偿还累计发生金额系采购设备等物资到货结转。 2、宁波益诺生智能制造有限公司属于曾与本公司实际控制人关系密切的家庭成员施加重大影响的其他企业，2020 年 11 月 3 日上述关联股权已全部对外转让于非关联自然人。截至 2023 年 6 月 30 日，虽已超过 12 个月不 存在上述关联情形，但为符合公司章程及关联交易决策制度的要求，经 2021 年第一次临时股东大会通过，本公司对其的交易仍将继续比照关联交易进行审议及披露。 法定代表人：_________ 主管会计工作负责人：________ 会计机构负责人（会计主管人员）：________ 单位：万元 非经营性资金占用 资金占用方名称 占用方与上 市公司的关 联关系 上市公司核 算的会计科 目 2023 年期 初占用资 金余额 2023 年 1-6 月 占用累计发 生金额（不含 利息） 2023 年 1-6 月占用资金 的利息(如 有) 2023 年 1-6 月偿还 累计发生 金额 2023 年 ...

国泰君安证券股份有限公司 关于宁波天益医疗器械股份有限公司 2023年半年度持续督导跟踪报告 | 保荐机构名称：国泰君安证券股份有限公司 | 被保荐公司简称：天益医疗 | | --- | --- | | 保荐代表人姓名：沈一冲 | 联系电话：021-38677509 | | 保荐代表人姓名：水耀东 | 联系电话：021-38676250 | | 1.公司信息披露审阅情况 | | | --- | --- | | (1) 是否及时审阅公司信息披露文件 | 是 | | (2) 未及时审阅公司信息披露文件的次数 | 0次 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | (1)是否督导公司建立健全规章制度(包括但不限 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度) | | | (2) 公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | (1) 查询公司募集资金专户次数 | 每月查询 | | (2)公司募集资金项目进展是否与信息披露文件一 | 是 | | 致 | | | 4.公司治理督导情况 | | | (1) 列席 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2023-039 宁波天益医疗器械股份有限公司 第三届董事会第五次会议决议公告 一、董事会会议召开情况 公司董事会在全面审核公司 2023 年半年度报告全文及其摘要后，一致认为： 公司 2023 年半年度报告及其摘要的内容真实、准确、完整地反映了公司 2023 年 半年度经营的实际情况，不存在虚假记载、误导性陈述或者重大遗漏；报告的编 制和审核程序符合法律、行政法规的要求，符合中国证监会及深圳证券交易所的 相关规定，同意对外报出。 宁波天益医疗器械股份有限公司(以下简称"公司")第三届董事会第五次会 议通知于 2023 年 8 月 15 日以电话、短信、电子邮件等方式向公司全体董事发 出。会议于 2023 年 8 月 25 日上午 10:00 在公司会议室召开。 具体内容详见同日在中国证监会指定创业板信息披露网站巨潮资讯网上发 布的相关公告。 本次会议应参会董事 7 名，实际参会董事 7 名，其中董事夏志强先生以通讯 方式参会。会议由董事长吴志敏先生召集和主持，部分高管列席了会议。本次会 议的召集、召开及表决程序符合有关法律、行政法规、部门规章、规范性文 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2023-038 宁波天益医疗器械股份有限公司 关于首发前限售股东减持计划期限届满的公告 股东上海金浦国调并购股权投资基金合伙企业（有限合伙）保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"、"公司"）于 2023 年 4 月 14 日在巨潮资讯网披露了《关于首发前限售股东减持计划的预披露 公告》（公告编号：2023-008），公司首发前限售股东上海金浦国调并购股权投 资基金合伙企业（有限合伙）（以下简称"金浦国调基金"）计划在公告披露之 日起 15 个交易日后的 3 个月内，以集中竞价及大宗交易方式减持公司股份不超 过 1,178,946 股（不超过公司股份总数的 2%），其中通过集中竞价方式减持的股 份总数不超过 589,473 股（不超过公司股份总数的 1%），通过大宗交易方式减 持的股份总数不超过 589,473 股（不超过公司股份总数的 1%）。 截至本公告披露之日，金浦国调基金之减持计划时间 ...

证券代码：301097 证券简称：天益医疗 宁波天益医疗器械股份有限公司 投资者关系活动记录表 编号：2023-001 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 形式 | ☐现场 网上 ☐电话会议 | | 参与单位名称及人员姓名 | 线上参与公司2022年度网上业绩说明会的投资者 | | 时间 | 2023年05月23日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/） | | 上市公司接待人员姓名 | 董事长、总经理 吴志敏 董事、副总经理、财务总监 张重良 | | | 副总经理、董事会秘书 李孟良 | | | 独立董事 奚盈盈 1.公司去年的分红方案是每10股派2.5元，今年在营收没 | | | 有明显增长的情况下，分红规模却超去年，是基于什么考 | | 投资者关系活动主要内容 | 量？ | | 介绍 | 回复:公司制定的利润分配预案是在保证公司正常经营 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2023-025 宁波天益医疗器械股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 宁波天益医疗器械股份有限公司（以下简称"公司"）已于 2023 年 04 月 21 日在巨潮资讯网上披露了《宁波天益医疗器械股份有限公司 2022 年年度报 告全文》及《宁波天益医疗器械股份有限公司 2022 年年度报告摘要》。为便于 广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 05 月 23 日（星期二）15:00-17:00 在"价值在线"（www.ir-online.cn ）举办宁波天益医疗器械股份有限公司 2022 年度网上业绩说明会，与投资者进 行沟通和交流，广泛听取投资者的意见和建议。 1 会议召开时间：2023 年 05 月 23 日（星期二）15:00-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会 议 问 题 征 集 ： 投 资 者 可 于 ...

宁波天益医疗器械股份有限公司 2023 年第一季度报告 证券代码：301097 证券简称：天益医疗 公告编号：2023-022 宁波天益医疗器械股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 宁波天益医疗器械股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 □会计政策变更 □会计差错更正 同一控制下企业合并 □其他原因 | | 本报告期 | 上年同期 | | 本报告期比上年同期 | | --- | --- | --- | --- | --- | | | | | | 增减（%） | | | | 调 ...

Financial Performance - The company’s operating revenue for 2022 was ¥399,325,371.39, a decrease of 3.71% compared to ¥414,731,858.47 in 2021[22]. - Net profit attributable to shareholders increased by 9.34% to ¥85,604,071.60 in 2022 from ¥78,292,042.29 in 2021[22]. - The net profit after deducting non-recurring gains and losses was ¥65,771,738.94, down 9.99% from ¥73,074,983.57 in the previous year[22]. - The net cash flow from operating activities decreased significantly by 62.28% to ¥50,177,065.73 from ¥133,029,877.97 in 2021[22]. - Basic earnings per share were ¥1.55, a decline of 12.43% from ¥1.77 in 2021[22]. - Total assets at the end of 2022 reached ¥1,627,081,762.90, an increase of 101.55% from ¥807,284,424.94 at the end of 2021[22]. - Net assets attributable to shareholders rose by 163.05% to ¥1,234,868,730.71 from ¥469,438,292.18 in 2021[22]. - The company reported a quarterly revenue of ¥120,493,264.29 in Q4 2022, showing a steady increase throughout the year[24]. - The company experienced a net loss of ¥1,407,761.26 in Q4 2022, contrasting with profits in the earlier quarters[24]. - The weighted average return on equity decreased to 8.36% in 2022 from 18.20% in 2021, indicating a decline in profitability[22]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.00 RMB per 10 shares to all shareholders, based on a total of 58,947,368 shares[3]. - The total distributable profit for the year was RMB 382,393,454.39, with the cash dividend amounting to 100% of the profit distribution[183]. - The company reported a cash dividend of RMB 5.00 per 10 shares, totaling RMB 29,473,684.00, which represents 100% of the total profit distribution[183]. - The company has a total of 58,947,368 shares, with no stock bonus or capital reserve conversion planned for this year[185]. Risk Management - The report emphasizes the importance of risk awareness regarding forward-looking statements and future plans[3]. - The company has a comprehensive risk management strategy outlined in the management discussion section, detailing potential operational risks and mitigation measures[3]. - The company is actively managing financial risks, including currency fluctuations, as a significant portion of its revenue comes from foreign sales settled in USD, which exposes it to exchange rate volatility[133]. - The company acknowledges potential risks from fluctuating gross margins, particularly in its main product lines, which could adversely affect profitability if production costs cannot be managed effectively[129]. - The company faces risks related to customer concentration, particularly with significant reliance on Avanos Medical for sales of feeding devices and tubes, which could impact order sustainability if this client reduces demand[130]. Research and Development - The company has a dedicated R&D team of 120 members, accounting for 10.70% of total employees, focusing on product development and technological innovation[69]. - The company invested a total of 28.06 million yuan in R&D during the reporting period, with R&D expenses accounting for 7.03% of operating revenue, representing a year-on-year increase of 38.50%[70]. - The company is focusing on developing domestic alternatives for imported blood purification products, which is expected to enhance competitiveness and reduce healthcare costs[95]. - R&D investment increased from ¥20,261,432.48 in 2021 to ¥28,061,366.99 in 2022, a year-on-year increase of 38.50%[96]. - The company has developed new products such as disposable integrated oxygen tubes and blood dialysis concentrates, achieving significant economic benefits while focusing on high-value products in the blood purification field[71]. Market Presence and Sales - The company has a significant market presence, covering over 1,000 hospitals and 450 top-tier hospitals across 31 provinces and municipalities in China[66]. - The company ranks second in the market share for extracorporeal circulation blood lines in China, indicating strong competitiveness in the industry[67]. - The company’s products are sold across all 31 provinces and regions in China and exported to Asia, Europe, North America, South America, and Africa[45]. - Domestic sales reached CNY 233.98 million, up 12.46% year-on-year, while overseas sales dropped by 20.00% to CNY 165.35 million[84]. - The blood purification segment generated revenue of CNY 220.37 million, accounting for 55.18% of total revenue, reflecting a decline of 16.10% year-on-year[83]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[138]. - The supervisory board is composed of 3 members, including 1 employee representative, ensuring compliance with legal standards[139]. - The company maintains independence in assets, personnel, finance, organization, and business from its controlling shareholders and actual controllers[144][145][146][147][148]. - The company has established a comprehensive internal control system, including rules for shareholder meetings and specialized committees to ensure effective governance[186]. - The company emphasizes transparency and timely information disclosure, adhering to relevant laws and regulations[141]. Quality Control and Compliance - The company has established a comprehensive quality control system, ensuring that no quality-related medical accidents or disputes occurred during the reporting period[75]. - The company has passed EN ISO 13485:2016 quality management system certification and has received EU MDR certification in January 2023, indicating compliance with international quality standards[75]. - The company emphasizes product quality by adhering to various medical device regulations and continuously improving its quality control system[197]. - The company has established a robust internal control system to ensure compliance with relevant laws and regulations[195]. - The company has no environmental penalties reported during the reporting period, indicating compliance with environmental regulations[194]. Social Responsibility and Employee Welfare - The company is committed to social responsibility and aims to contribute positively to community welfare while ensuring employee satisfaction[128]. - The company promotes a work-life balance and fosters a positive work environment through various employee care activities[200]. - The company aims to create a harmonious work environment while promoting employee development through targeted training programs[180]. - The company emphasizes the importance of customer needs and employee well-being while actively fulfilling social responsibilities[125]. - The company adheres to labor laws and regulations, ensuring fair treatment of employees and prohibiting child labor and forced labor[199].

Financial Performance - The company's revenue for Q3 2022 was CNY 106,166,400.56, a decrease of 10.82% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2022 was CNY 43,195,485.31, an increase of 45.60% year-on-year[5]. - The basic earnings per share for Q3 2022 was CNY 0.80, reflecting a growth of 19.13% compared to the previous year[5]. - Total revenue for the third quarter was CNY 278,832,107.10, a decrease of 6.4% compared to CNY 297,263,653.44 in the same period last year[29]. - The net profit for the third quarter of 2022 was CNY 87,104,476.44, an increase of 54.6% compared to CNY 56,394,447.39 in the same period last year[30]. - The total comprehensive income attributable to the parent company was CNY 87,264,292.63, compared to CNY 56,394,447.39 in the same quarter last year[30]. - The company reported a net profit margin improvement, with net profit increasing significantly due to reduced costs and increased operating efficiency[29]. Assets and Equity - Total assets at the end of Q3 2022 reached CNY 1,588,300,645.89, representing a significant increase of 96.75% year-on-year[5]. - Shareholders' equity attributable to the parent company increased by 163.41% year-on-year, amounting to CNY 1,236,528,951.74[5]. - Total assets increased significantly to CNY 1,588,300,645.89 from CNY 807,284,424.94, marking an increase of 96.5%[27]. - The company's equity attributable to shareholders increased to CNY 1,236,528,951.74 from CNY 469,438,292.18, a substantial increase of 163.5%[27]. Cash Flow - Cash flow from operating activities decreased by 61.06% year-to-date, primarily due to declining cash inflows from revenue and increased cash outflows for expenses[10]. - The cash flow from operating activities showed a net inflow of CNY 38,936,019.62, down 61.0% from CNY 99,994,387.20 in the prior year[31]. - The cash and cash equivalents at the end of the period amounted to CNY 470,407,387.02, up 89.5% from CNY 248,156,307.34 at the end of the previous year[32]. - The company experienced a cash inflow of CNY 1,085,475,371.56 from financing activities, a substantial increase from CNY 203,500,000.00 in the previous year[32]. Investment and Development - The company plans to invest approximately RMB 500 million in the Ningxiang High-tech Industrial Park to establish a manufacturing base for blood dialysis consumables and ICU continuous blood purification equipment[18]. - The company is actively engaged in planning and project bidding for the Ningxiang manufacturing base, in compliance with relevant regulations[18]. - The company is currently in the registration review stage for a Class III blood purification pipeline, which is an upgrade of an existing product[23]. - The company has a total of 5 new products under development, including a Class II gastrointestinal nutrition infusion pipeline and a Class II nasal feeding tube[23]. - The company is focused on improving patient outcomes through the development of specialized medical devices[23]. - Future outlook includes continued investment in new product development and market expansion strategies to drive growth[29]. Regulatory and Market Presence - The company has established a subsidiary in Singapore and plans to set up a subsidiary in Hong Kong, enhancing its international market presence and competitiveness[19]. - The company received a Class III medical device registration certificate for the disposable blood dialysis tubing on September 19, 2022, valid for five years until September 18, 2027[20]. - The company reported a total of 28 registered medical devices, with various classifications including Class II and Class III[21]. - The company has received multiple approvals for its medical devices, ensuring compliance with regulatory standards[21]. - The company aims to enhance its market presence through strategic product development and regulatory approvals[22]. - The company is committed to continuous innovation in medical technology to meet evolving healthcare needs[23]. Operating Costs and Efficiency - Total operating costs decreased to CNY 209,151,373.23 from CNY 235,654,235.86, reflecting a reduction of 11.2%[29]. - Operating profit increased to CNY 100,959,416.63, up from CNY 64,912,235.60, representing a growth of 55.5%[29]. - Research and development expenses were CNY 18,817,200.85, compared to CNY 15,907,337.94 in the previous year, reflecting a growth of 17.9%[29].